LANREOTIDE ACETATE Drug Patent Profile

When do Lanreotide Acetate patents expire, and when can generic versions of Lanreotide Acetate launch?

Lanreotide Acetate is a drug marketed by Invagen Pharms and is included in two NDAs.

The generic ingredient in LANREOTIDE ACETATE is lanreotide acetate. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lanreotide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lanreotide Acetate

A generic version of LANREOTIDE ACETATE was approved as lanreotide acetate by INVAGEN PHARMS on December 17^th, 2021.

Summary for LANREOTIDE ACETATE

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	25
Clinical Trials:	4
Patent Applications:	694
What excipients (inactive ingredients) are in LANREOTIDE ACETATE?	LANREOTIDE ACETATE excipients list
DailyMed Link:	LANREOTIDE ACETATE at DailyMed

Recent Clinical Trials for LANREOTIDE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Debiopharm International SA	Phase 1
Ipsen	Phase 1/Phase 2
Ipsen	Phase 3

See all LANREOTIDE ACETATE clinical trials

Pharmacology for LANREOTIDE ACETATE

Drug Class	Somatostatin Analog
Mechanism of Action	Somatostatin Receptor Agonists

Anatomical Therapeutic Chemical (ATC) Classes for LANREOTIDE ACETATE

H01CB	Somatostatin and analogues
H01C	HYPOTHALAMIC HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

US Patents and Regulatory Information for LANREOTIDE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-001	May 21, 2024	AB	RX	No	No
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-002	Dec 17, 2021		RX	Yes	Yes
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-001	Dec 17, 2021		RX	Yes	Yes
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-002	May 21, 2024	AB	RX	No	No
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	215395-003	Dec 17, 2021		RX	Yes	Yes
Invagen Pharms	LANREOTIDE ACETATE	lanreotide acetate	SOLUTION;SUBCUTANEOUS	217193-003	May 21, 2024	AB	RX	No	No

Market Dynamics and Financial Trajectory for Lanreotide Acetate

Last updated: February 19, 2026

What is the current market size and growth potential for lanreotide acetate?

Lanreotide acetate is a synthetic somatostatin analog used primarily for acromegaly and neuroendocrine tumors (NETs). As of 2022, the global market for somatostatin analogs, including lanreotide acetate, is valued at approximately USD 1.2 billion. The compound represents about 65% of this segment, with octreotide marketed primarily by Novartis and Ipsen producing lanreotide. The compound’s segment is expected to grow at a CAGR of 5% through 2028, driven by rising diagnosis rates and expanded approvals.

What are the key indications influencing market demand?

Primarily, lanreotide acetate treats:

• Acromegaly
• Gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

The increase in diagnosis of acromegaly, which affects roughly 3 to 4 people per million annually, boosts demand. The expanding use of lanreotide for GEP-NETs, supported by guidelines from organizations like NANETS, accelerates sales growth.

How does competitive positioning impact financial prospects?

Ipsen's Lanreotide (Somatuline Depot) dominates sales, with global revenue of USD 600 million in 2022, accounting for about 50% of the segment. Novartis’ octreotide remains the market leader, overshadowing lanreotide in some indications.

Lanreotide's patent protection expired in most jurisdictions by 2022. However, the extended-release formulation's exclusivity remains until 2024 in the U.S., influencing revenue stability. Biosimilar competition is emerging, potentially reducing prices by 20-30%.

What are the regulatory and pipeline influences on future revenue?

Regulatory approvals expanded in 2021 and 2022:

• European approval for extended indications, including carcinoid syndrome.
• U.S. FDA approval for use in certain pancreatic NETs.

Pipeline developments include:

• Subcutaneous formulations aiming for increased patient convenience.
• Combinations with targeted therapies for broader anti-tumor activity.

These advancements could extend the product lifecycle and revenue streams.

What financial risks and opportunities are present?

Risks:

• Patent expiry leading to biosimilar entry, forecasted around 2024, could erode market share.
• Pricing pressures due to healthcare cost containment policies.
• Competition from emerging peptide-based therapies.

Opportunities:

• Growing market in emerging economies, which accounted for approximately 25% of sales in 2022.
• New indications for tumor types like pancreatic and lung neuroendocrine tumors.
• Entry into combination therapies with immunotherapeutic agents.

How do manufacturing and supply chain factors influence profitability?

Lanreotide acetate production involves complex peptide synthesis requiring high-purity raw materials. Supply chain disruptions, such as shortages of raw materials like amino acids or catalysts, can increase costs. Ensuring supply chain resilience can protect margins, especially if biosimilar competitors reduce prices.

What is the financial outlook?

Projected global sales for lanreotide acetate and similar formulations are expected to reach USD 1.8 billion by 2030, driven by expanded indications and geographic penetration. Compound annual growth rate estimates suggest a CAGR of 5% from 2022 to 2030, assuming successful pipeline and market penetration.

Key Takeaways

• The global lanreotide acetate market is approximately USD 780 million as of 2022, with strong growth prospects.
• Patent expiration and biosimilar competition pose significant revenue risks starting from 2024.
• Expanded indications and increased adoption in emerging markets present substantial opportunities.
• Competitive positioning is shaped by regulatory decisions, pipeline innovations, and pricing pressures.
• Supply chain reliability remains critical to maintaining profit margins amid increasing demand and competition.

FAQs

1. When does lanreotide acetate lose patent protection, and how will it impact the market?
Patent protections expire around 2024 in most regions, opening the door for biosimilar competitors that could reduce prices and market share.

2. How does biosimilar competition affect pricing strategies?
Biosimilars tend to lower prices by 20-30%, forcing incumbent manufacturers to adjust pricing or increase value through new indications and formulations.

3. Are there approved new indications for lanreotide acetate?
Yes, approvals since 2021 include additional neuroendocrine tumor types and carcinoid syndrome, broadening the potential market.

4. What emerging markets offer growth opportunities?
Regions such as China and Brazil show increased adoption, driven by expanding healthcare infrastructure and awareness, representing roughly 25% of sales as of 2022.

5. How does pipeline development influence future revenue?
New formulations, combination therapies, and broader scope indications could extend market relevance and revenue beyond 2030.

---

References

1. MarketWatch. (2022). "Global market for somatostatin analogs."
2. Ipsen. (2022). "Financial report."
3. NANETS. (2022). "Guidelines for neuroendocrine tumor management."
4. FDA. (2022). "Drug approvals and indications."
5. Novartis. (2022). "Octreotide sales data."